The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer

References

• Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563–72
   PubMed Web of Science ®Google Scholar
• Andersen J, Poulsen HS. Relationship between estrogen receptor status in the primary tumour and its regional and distant metastases. An immunohistochemical study in human breast cancer. Acta Oncol 1988; 27: 761–5
   PubMed Web of Science ®Google Scholar
• Kamby C, Rasmussen BB, Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 1989; 60: 252–7
   PubMed Web of Science ®Google Scholar
• Nedergaard L, Haerslev T, Jacobsen GK. Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies. APMIS. 1995; 103: 20–4
   PubMed Web of Science ®Google Scholar
• Buxant F, Anaf V, Simon P, Fayt I, Noel JC. Ki-67 immunostaining activity is higher in positive axillary lymph nodes than in the primary breast tumor. Breast Cancer Res Treat 2002; 75: 1–3
   PubMedGoogle Scholar
• Park D, Karesen R, Noren T, Sauer T. Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: Clinical implications. Virchows Arch 2007; 451: 11–8
   PubMedGoogle Scholar
• Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004; 90: 2344–8
   PubMed Web of Science ®Google Scholar
• Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415–30
   PubMed Web of Science ®Google Scholar
• el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998; 8: 345–57
   PubMed Web of Science ®Google Scholar
• Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Lee HK, et al. Immunohistochemical analysis of fas ligand expression in normal human tissues. APMIS 1999; 107: 1013–9
   PubMed Web of Science ®Google Scholar
• Xerri L, Devilard E, Hassoun J, Mawas C, Birg F. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with fas in various epithelial tissues. Mol Pathol 1997; 50: 87–91
   PubMedGoogle Scholar
• Igney FH, Krammer PH. Tumor counterattack: Fact or fiction?. Cancer Immunol Immunother 2005; 54: 1127–36
   PubMed Web of Science ®Google Scholar
• Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996; 56: 4791–8
   PubMedGoogle Scholar
• Herrnring C, Reimer T, Jeschke U, Makovitzky J, Kruger K, Gerber B, et al. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochem Cell Biol 2000; 113: 189–94
   PubMedGoogle Scholar
• Mullauer L, Mosberger I, Grusch M, Rudas M, Chott A. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J Pathol 2000; 190: 20–30
   PubMed Web of Science ®Google Scholar
• Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194–201
   PubMed Web of Science ®Google Scholar
• Sjöström J, Blomqvist C, von Boguslawski K, Bengtsson NO, Mjaaland I, Malmstrom P, et al. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res 2002; 8: 811–6
   PubMed Web of Science ®Google Scholar
• Weigelt B, Wessels LF, Bosma AJ, Glas AM, Nuyten DS, He YD, et al. No common denominator for breast cancer lymph node metastasis. Br J Cancer 2005; 93: 924–32
   PubMed Web of Science ®Google Scholar
• Weinberg RA. Mechanisms of malignant progression. Carcinogenesis 2008; 29: 1092–5
   PubMedGoogle Scholar
• Ioachim HL, Decuseara R, Giancotti F, Dorsett BH. FAS and FAS-L expression by tumor cells and lymphocytes in breast carcinomas and their lymph node metastases. Pathol Res Pract 2005; 200: 743–51
   PubMedGoogle Scholar